Figure 3B shows the highest plotted mean serum antibody concentrations for the 03-135 formulation at 24 and 48 hours. This is a qualitative comparison of the plotted means; the figure does not report a between-lipid statistical significance test.
sales@dcchemicals.com
Lipid 03-135
Formulation & Performance
mRNA1 delivery · mouse expression study
| Cargo | mRNA1 encoding a CD19/CD3 bispecific antibody |
| Model | NOD/SCID mice |
| Administration | Intravenous (tail vein), single dose |
| Dose | 1 μg mRNA per mouse |
| Comparators | 01-1, 03-208, 02-1 and 02-3 |
| N/P ratio | Not reported for this experiment |
| Exact formulation | 03-135 with helper lipids described in Example 2. Component molar percentages and exact PEG-lipid identity are not resolved for Figure 3B. |
The result supports intravenous mRNA-encoded antibody delivery research. This patent does not disclose a 03-135-specific subcutaneous or monkey experiment. The antitumor experiment in Figure 4 uses lipid 01-1.
Original patent and figures: WO2024131874A1
Source: WO2024131874A1, Figure 3B, PDF p. 137; Example 7, paragraph [0362].
Values shown are literature-reported results for the cited formulation and study conditions. They do not guarantee performance of the supplied product in other formulations or experiments.